Completed PHASE3 NCT00080340

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Telik

Conditions Non Small Cell Lung Carcinoma

Interventions TLK286 (Telcyta) HCl for Injection gefitinib (Iressa)

Updated 6 times since 2017 Last updated: Jan 10, 2008 Completion: May 31, 2005

This PHASE3 trial investigates Non Small Cell Lung Carcinoma and is currently completed. Telik leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Telik

Data source: Telik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Albury, Australia , Altamonte Springs, United States , Ann Arbor, United States , Annapolis, United States , Antioch, United States , Arlington, United States , Armonk, United States , Atlanta, United States and 207 more locations